- Home
- CB vs GSK Comparison
CB vs GSK Comparison
Compare CB & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$52.50
Company Overview
Basic Information| Metric | CB | GSK |
|---|---|---|
| Founded | 1985 | 1715 |
| Country | Switzerland | United Kingdom |
| Employees | N/A | 66841 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.9B | 108.7B |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | CB | GSK |
|---|---|---|
| Price | $326.44 | $52.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 2 |
| Target Price | ★ $332.76 | N/A |
| AVG Volume (30 Days) | 1.5M | ★ 3.6M |
| Earning Date | 04-21-2026 | 04-29-2026 |
| Dividend Yield | 1.19% | ★ 3.40% |
| EPS Growth | ★ 13.13 | N/A |
| EPS | ★ 5.88 | N/A |
| Revenue | ★ $59,402,000,000.00 | N/A |
| Revenue This Year | N/A | $6.99 |
| Revenue Next Year | $5.31 | $4.19 |
| P/E Ratio | $55.81 | ★ $32.75 |
| Revenue Growth | ★ 6.54 | N/A |
| 52 Week Low | $264.10 | $35.45 |
| 52 Week High | $345.67 | $61.70 |
Technical Indicators
Market Signals| Indicator | CB | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 54.57 | 55.31 |
| Support Level | $317.41 | $48.02 |
| Resistance Level | $335.01 | $59.97 |
| Average True Range (ATR) | 6.28 | 0.75 |
| MACD | 1.37 | 0.40 |
| Stochastic Oscillator | 73.70 | 80.53 |
Price Performance
Historical Comparison CB
GSK
About CB Chubb Limited
ACE acquired Chubb in 2016 and assumed the Chubb name. The combination made the new Chubb one of the largest domestic property and casualty insurers, with operations in over 50 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
About GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.